Voluntary Recall of Robaxin 750 mg Due to Dosage Misprint
TUESDAY, Oct. 2, 2018 -- Endo Pharmaceuticals is voluntarily recalling two lots of Robaxin (methocarbamol tablets) 750 mg tablets (100-count bottles) due to incorrect dosage information. According to the recall notice, the products have incorrect... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 2, 2018 Category: Pharmaceuticals Source Type: news

Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin ® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label
Endo International plc (NASDAQ: ENDP) today announced that one of its operating companies, Endo Pharmaceuticals Inc., is voluntarily recalling two lots of Robaxin ® (methocarbamol tablets, USP) 750mg Tablets 100 Count Bottle pack to the consumer level. The products have been found to have incorrect daily dosing information on the label due to a labeling error which misstates the daily dose as " two to four tablets four times daily " rather than the correct dosage of " two tablets three times daily. " (see picture below for location of incorrect text). (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 28, 2018 Category: Food Science Source Type: news

Methocarbamol Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - November 6, 2017 Category: Drugs & Pharmacology Source Type: news

Robaxin vs. Flexeril
Title: Robaxin vs. FlexerilCategory: MedicationsCreated: 11/1/2017 12:00:00 AMLast Editorial Review: 11/1/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - November 1, 2017 Category: Drugs & Pharmacology Source Type: news

Robaxin (Methocarbamol) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 30, 2016 Category: Drugs & Pharmacology Source Type: news

Reumofan Plus USA, LLC and Reumofan USA, LLC is Voluntarily Recalling all lots of Reumofan Plus Tablets Due to Undeclared Drug Ingredients
Feb. 15, 2013 - SPRINGFIELD, Pa., /PRNewswire/-- Reumofan Plus USA, LLC and Reumofan USA, LLC is recalling "Reumofan Plus" Tablets, Lot# 99515, exp. 09/16, because they contain undeclared active pharmaceutical ingredients: methocarbamol, dexamethasone, and diclofenac. Use of this product could result in serious and life-threatening injuries (Source: Food and Drug Administration)
Source: Food and Drug Administration - February 19, 2013 Category: Food Science Source Type: news

Reumofan Plus: Recall - Undeclared Drug Ingredient
[UPDATED 2/19/2013] Reumofan Plus USA, LLC and Reumofan USA, LLC is recalling "Reumofan Plus" Tablets, Lot# 99515, exp. 09/16, because they contain undeclared active pharmaceutical ingredients: methocarbamol, dexamethasone, and diclofenac. The... (Source: Drugs.com - FDA MedWatch Alerts)
Source: Drugs.com - FDA MedWatch Alerts - February 19, 2013 Category: Drugs & Pharmacology Source Type: news